Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]-NOTA-hGZP PET Imaging in Cancer Patients on Checkpoint Inhibitors
NCT04169321Phase 1Completed
- Sponsor
- CytoSite Bio
- Start
- Jun 2020
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of gallium-68 NOTA hGZP in solid tumor and lymphoma, sponsored by CytoSite Bio. Primary endpoints: Number of participants with clinically meaningful changes in physical examination findings, vital signs or blood chemistry, Number of participants with changes in ECG and 1 more. Started Jun 2020; status: completed.
02
Drugs
gallium-68 NOTA hGZP
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04169321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169321.